Loading...
XOSL
GENT
Market cap83mUSD
Dec 04, Last price  
55.00NOK
1D
2.61%
1Q
-1.79%
Jan 2017
3.77%
IPO
96.43%
Name

Gentian Diagnostics ASA

Chart & Performance

D1W1MN
XOSL:GENT chart
P/E
18.73
P/S
5.58
EPS
2.94
Div Yield, %
Shrs. gr., 5y
0.46%
Rev. gr., 5y
25.96%
Revenues
152m
+11.66%
22,893,74224,554,41625,586,95430,896,88734,988,95946,108,22047,952,00068,369,00083,122,000101,636,000136,193,000152,070,000
Net income
45m
P
873,987-2,908,559-3,222,155-8,926,987-15,169,906-19,798,354-39,857,000-17,114,000-24,794,000-24,001,000-10,648,00045,293,000
CFO
13m
-12.94%
2,433,754-1,950,715-4,626,008-7,901,630-18,632,886-10,896,653-21,483,000-7,661,000-27,053,000-13,952,00015,458,00013,457,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Gentian Diagnostics ASA researches, develops, and produces biochemical reagents for use in medical diagnostics and research in Europe, Asia, and the United States. It offers in-vitro diagnostic reagents for clinical chemistry analyzers. The company's products include the gentian calprotectin immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Cystatin C, a superior GFR marker for the diagnosis and therapeutic control of renal function; NT-proBNP Immunoassay for diagnosis, monitoring, and assessment of severity in individuals suspected of having congestive heart failure; and Canine c-reactive protein (CRP) immunoassay, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine CRP in dog plasma and serum. It also provides turbidimetric SARS-CoV-2 total antibody immunoassay, a quantitative antibody test for detecting antibodies targeting the S1-subunit. The company was incorporated in 2001 and is headquartered in Moss, Norway.
IPO date
Dec 14, 2016
Employees
55
Domiciled in
NO
Incorporated in
NO

Valuation

Title
NOK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT